|
|
|
Welcome to the Quality Counts. For those health conscious consumers and medical professionals that are looking to purchase nutritional supplements, vitamins, herbs, learning about medications, losing weight, health food, low carbs, high protein nutrition, and exercise, you have come to the right place. Quality Counts serves both the medical practitioner and consumer interested in nutritional therapy and alternative medicine.
Home > Health Conditions > Breast Cancer > Femara.
Femara (letrozole) - 1/01
Related Topics:
Where to purchase:
CME:
For Aromatization (in males):
-
Drugs for hair loss and benign prostatic hyperplasia may result in loss of
libido, erectile dysfunction in men - Science Daily, 1/11/11 -
"5a-reductase inhibitors (5a-RIs), while improving
urinary symptoms in patients with benign prostatic hyperplasia (BPH) and
possible hair loss prevention, produces significant adverse effects in some
individuals including loss of libido, erectile dysfunction (ED), ejaculatory
dysfunction and potential depression" - Note: That goes back
and forth. One study claimed that finasteride improved sex after after
six months of taking it. Regarding gynaecomastia, if you're taking low
dose letrozole to increase testosterone and to prevent aromatization it many
also help prevent gynaecomastia.
-
Prostate Drug May Not Dim Sex - WebMD, 6/26/07 - "Six months after the men started taking their assigned drugs, the survey
scores were about three points higher for the men taking Proscar. By the end
of the study, that gap narrowed to about two points"
-
Prostate Drug Doesn't Limit Sexual Function In Most Men - Science Daily,
7/19/07 - "The study suggests that finasteride will
cause little or no sexual dysfunction for most men who decide to take it"
-
Ask a Medical Question - Can letrozole cure gynecomastia - JustAnswer -
"Letrozole may be effective in preventing and
reversing the gynaecomastia provided it is used early enough in steroid
induced gynaecomastia" - See letrozole at
OffshoreRX.com.
I believe the recommended dose is something like a quarter tablet every
three days but don't quote me on it. That's what I take.
-
Aromatase Inhibition Offers Little Benefit, Possible Harm to Men With Lo...
- Medscape, 12/22/09 - "The inescapable conclusion from
these data is that the 50% increase in testosterone levels was trumped by the
much more modest 20% reduction in estradiol levels, leading to negative skeletal
effects of anastrozole therapy in aging men" - Note: I'm not sure
that thought this though thoroughly. Mortally in men is best when estrogen
is around 25pg/mL. I suspect that most have higher estrogen than that.
See:
-
High, Low Estradiol Levels and Mortality in Men With Systolic HF -
Medscape, 5/19/09 - "Both low and high serum levels
of estradiol, compared with mid-range levels, are significantly and
independently associated with increased all-cause mortality in men with
chronic systolic heart failure"
Serum Estradiol Concentration Quintiles as Predictors of All-Cause
Mortality in Men (With Quintile 3 as the Reference Group)
| Parameter |
Quintile 1 |
Quintile 2 |
Quintile 3 |
Quintile 4 |
Quintile 5 |
| Estradiol concentration (pg/mL) |
<12.903 |
12.90–21.79 |
21.80–30.11 |
30.12–37.39 |
>37.40 |
| 3-y survival* (%) |
44.6 |
65.8 |
82.4 |
79.0 |
63.6 |
| Quintile as mortality predictor,* HR (95% CI) vs quintile 3 |
4.17 (2.33–7.45) |
2.15 (1.16–3.99) |
-- |
1.22 (0.64–2.31) |
2.33 (1.30–4.18) |
HR= hazard ratio
- High, Low Estradiol Levels and Mortality in Men With Systolic HF - Medscape,
5/19/09 - "Both low and high serum levels of estradiol,
compared with mid-range levels, are significantly and independently associated
with increased all-cause mortality in men with chronic systolic heart failure"
- Note: See my aromatization page
for ways to reduce it. I take a quarter tablet of letrozole every day.
See
letrozole at OffshoreRX.com
 .
Serum Estradiol Concentration Quintiles as Predictors of All-Cause
Mortality in Men (With Quintile 3 as the Reference Group)
| Parameter |
Quintile 1 |
Quintile 2 |
Quintile 3 |
Quintile 4 |
Quintile 5 |
| Estradiol concentration (pg/mL) |
<12.903 |
12.90–21.79 |
21.80–30.11 |
30.12–37.39 |
>37.40 |
| 3-y survival* (%) |
44.6 |
65.8 |
82.4 |
79.0 |
63.6 |
| Quintile as mortality predictor,* HR (95% CI) vs quintile 3 |
4.17 (2.33–7.45) |
2.15 (1.16–3.99) |
-- |
1.22 (0.64–2.31) |
2.33 (1.30–4.18) |
HR= hazard ratio- Obesity Linked To Hormone Imbalance That Impacts Sexual Quality Of Life
- Science Daily, 3/3/09 - "In our study population,
we found that lower testosterone levels and diminished ratings for sexual
quality of life were correlated with increased BMI ... Subjects who lost
weight through bariatric surgery experienced a reduction in estradiol
levels, an increase in testosterone levels and an increase in ratings of
sexual quality of life" - See my
aromatization page.
-
Short-term
aromatase inhibition: effects on glucose metabolism and serum leptin levels in
young and elderly men - Eur J Endocrinol. 2008 Dec 2 -
"Ten elderly and nine young healthy men were randomized
to receive letrozole 2.5 mg daily or placebo for 28 days in a crossover design.
Results: Both in young and elderly men, active treatment significantly increased
serum testosterone (+128 and +99%, resp.) and decreased estradiol levels (-41
and -62%, resp.). Fasting glucose and insulin levels decreased in young men
after active intervention (-7 and -37%, resp.) compared to placebo. Leptin
levels fell markedly in both age groups (-24 and -25%, resp.), while adiponectin
levels were not affected by the intervention. Lipid profile was slightly
impaired in both groups, with increasing LDL-cholesterol levels (+14%) in the
younger age group and 10% lower levels of ApoA1 in the elderly. A decline in
IGF-1 levels (-15%) was observed in the younger age group. No changes in weight
or BMI were observed in either young or old men" - See
letrozole at OffshoreRX.com.
-
Letrozole once a week normalizes serum testosterone in obesity-related male
hypogonadism - Eur J Endocrinol. 2008 May;158(5):741-7 -
"Isolated hypogonadotropic hypogonadism (IHH) is
frequently observed in severely obese men, probably as a result of increased
estradiol (E(2)) production and E(2)-mediated negative feedback on pituitary
LH secretion. Aromatase inhibitors can reverse this process ... treated with
2.5 mg letrozole once a week for 6 months ... Six weeks of treatment reduced
total E(2) from 123+/-11 to 58+/-7 pmol/l (P<0.001, mean+/-s.e.m.), and
increased serum LH from 4.4+/-0.6 to 11.1+/-1.5 U/l (P<0.001). Total
testosterone rose from 5.9+/-0.5 to 19.6+/-1.4 nmol/l (P<0.001), and free
testosterone from 163+/-13 to 604+/-50 pmol/l (P<0.001). Total testosterone
rose to within the normal range in all subjects, whereas free testosterone
rose to supraphysiological levels in 7 out of 12 men ... Letrozole 2.5 mg
once a week produced a sustained normalization of serum total testosterone
in obese men with IHH. However, free testosterone frequently rose to
supraphysiological levels. Therefore, a starting dose <2.5 mg once a week is
recommended" - See
.
-
Letrozole suppresses plasma estradiol and estrone sulphate more completely
than anastrozole in postmenopausal women with breast cancer - J Clin
Oncol. 2008 Apr 1;26(10):1671-6 - "Letrozole reduces
plasma E2 and E1S levels to a significantly greater extent than anastrozole"
- See
.
-
Comparative assessment in young and elderly men of the gonadotropin response
to aromatase inhibition - J Clin Endocrinol Metab. 2005
Oct;90(10):5717-22 - "As assessed after 28 d of
treatment, letrozole lowered E2 by 46% in the young men (P = 0.002) and 62%
in the elderly men (P < 0.001). In both age groups, letrozole, but not
placebo, significantly increased LH levels (339 and 323% in the young and
the elderly, respectively) and T (146 and 99%, respectively) (P value of
young vs. elderly was not significant). Under letrozole, peak LH response to GnRH was 152 and 52% increase from baseline in young and older men,
respectively"
-
Letrozole normalizes serum testosterone in severely obese men with
hypogonadotropic hypogonadism - Diabetes Obes Metab. 2005 May;7(3):211-5
- "Six weeks of treatment decreased
serum estradiol from 120 +/- 20 to 70 +/- 9 pmol/l (p = 0.006). None of the
subjects developed an estradiol level of less than 40 pmol/l. LH increased
from 4.5 +/- 0.8 to 14.8 +/- 2.3 U/l (p < 0.001). Total testosterone rose
from 7.5 +/- 1.0 to 23.8 +/- 3.0 nmol/l (p < 0.001) without a concomitant
change in sex hormone-binding globulin level. Those treated with Letrozole
17.5 mg per week had an excessive LH response" - Note: A
half tablet per day would be 8.75 mg/week. I believe 40 pmol/l of
estradiol is
11.54
pg/mL and the normal value for men is
10 to 52 pg/mL (Quest
says
10 to 50).
The way I read that, testosterone tripled. See
Femara at International Anti-aging Systems
or
Letrozole 2.5mg (Generic Equivalent of Femara 2.5mg ), at OffshoreRx.com.
-
Influence of letrozole
and anastrozole on total body aromatization and plasma estrogen levels in
postmenopausal breast cancer patients evaluated in a randomized, cross-over
study - J Clin Oncol. 2002 Feb 1;20(3):751-7 -
"estrone (E(1)), estradiol (E(2)), and estrone sulfate (E(1)S) ... Treatment
with anastrozole suppressed plasma levels of E(1), E(2), and E(1)S by a mean
of 81.0%, 84.9%, and 93.5%, respectively, whereas treatment with letrozole
caused a corresponding decrease of 84.3%, 87.8% and 98.0%, respectively. The
suppression of E(1) and E(1)S was found to be significantly better during
treatment with letrozole compared with anastrozole"
-
Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects
- J Clin Endocrinol
Metab. 1993 Aug;77(2):319-23 - "A reduction in
estradiol levels by about 30% from baseline was observed at the lowest dose
(0.02 mg)" - CGS 20 267 is Letrozole.
-
Letrozole-Femara - isteroids.com -
"Letrozole is
probably the most powerful Aromatase Inhibitor used by athletes today"
-
Femara (Letrozole)
clinical pharmacology - RxList.com - "Letrozole's
terminal elimination half-life is about 2 days and steady-state plasma
concentration after daily 2.5 mg dosing is reached in 2-6 weeks"
News & Research:
-
Joint Supplements for
Aromatase Inhibitor Adverse Effects - Medscape, 11/18/11 -
"Aromatase inhibitors are widely used in the
treatment of breast cancer but are associated with significant
musculoskeletal adverse effects, including joint pain and stiffness ... We
know that these symptoms are unresponsive to conventional pain medication
and often lead to low adherence to aromatase inhibitor therapy ... The
cohort consisted of postmenopausal breast cancer patents with stage I to III
disease who had been on aromatase therapy for at least 3 months, who
reported a pain rating of 4 or higher on a 10-point visual analog scale, and
whose pain worsened after initiating treatment with aromatase inhibitors if
they had preexisting osteoarthritis ... Participants took 1500 mg/day of
glucosamine and 1200 mg/day of chondroitin, and were evaluated every 6 weeks
at the clinic ... There was a drop in pain and stiffness in the hips and
knees at 12 and 24 weeks, as well as improvement in function. "This affected
about 50% of the women," she explained. "We saw a very similar pattern
looking at the hands and the wrist. We saw similar results with the Brief
Pain/Stiffness Inventory — with about 35% to 50% of women."" - See
glucosamine products at iHerb
and
chondroitin products at iHerb.
-
Breast Cancer Survival: Femara Better Than Tamoxifen - WebMD, 10/21/11 -
"At an average follow-up of more than eight years,
postmenopausal women who took Femara for five years after surgery were 20%
less likely to have their breast cancer return and 21% less likely to die
from their breast cancer compared to postmenopausal women who too"
-
Aromatase inhibitor letrozole guards against breast cancer relapse for up to
8 years, study finds
- Science Daily, 9/25/11
Toxicity of aromatase inhibitors may explain lack of overall survival
improvement - Science Daily, 8/22/11 - "compared
to tamoxifen, longer use of AIs was
associated with increased heart disease and bone fractures, but lower rates
of blood clots and cancer of the womb. There were no differences in the risk
of stroke or other types of cancer. Furthermore, use of AIs for 2-3 years
after initial treatment with tamoxifen was associated with a lower risk of
death unrelated to breast cancer compared to the use of either AIs or
tamoxifen alone. The authors therefore concluded that the toxicity of AIs
when used for longer periods of treatment may explain the lack of overall
survival benefit while still having a positive effect on breast cancer
recurrence"
Vitamin
D relieves joint, muscle pain for breast cancer patients - Science Daily,
7/26/11 - "Rastelli's group recruited 60 patients who reported pain and
discomfort associated with anastrozole, one of three FDA-approved aromatase
inhibitors. The patients they studied also had low vitamin D levels. Half the
group was randomly assigned to receive the recommended daily dose of vitamin D
(400 international units) plus a 50,000-unit vitamin D capsule once a week. The
other half received the daily dose of 400 units of vitamin D plus a weekly
placebo. All subjects received 1,000 milligrams of calcium daily throughout the
study ... patients receiving high-dose vitamin D every week reported
significantly less musculoskeletal pain and also were less likely to experience
pain that interfered with daily living" - See
vitamin D products at iHerb.
Exemestane reduces breast cancer in high-risk women, researchers show -
Science Daily, 6/4/11 - "The study showed that in postmenopausal women at
increased risk of breast cancer, but who have not previously been diagnosed with
breast cancer, the aromatase inhibitor called Aromasin, made by Pfizer, reduces
this risk by 65 percent compared with placebo" - Note: If you go the the
abstract is says "Funded by Pfizer and others" and like it says, Aromasin
(exemestane) is made by Pfizer. I've always thought of Aromasin
(exemestane) as being cheaper and less effective than Femara (letrozole) which
is made by Novartis. A good study would have included Femara.
Femara vs. Tamoxifen for Breast Cancer - WebMD, 8/19/09
Letrozole Plus FSH a
"Good Initial Option" in Older Infertile Women - Medscape, 7/8/09
Cognitive Function Better With Letrozole Than With Tamoxifen in Patients
Treated for Breast Cancer - Doctor's Guide, 6/1/09
Late
Treatment With Letrozole Can Reduce Breast Cancer Recurrence Risk -
Science daily, 3/10/08
Ki-67 Expression Appears to Identify Breast Cancer Patients That Would
Benefit From Letrozole Rather Than Tamoxifen - Doctor's Guide, 12/17/07
Vitamin D Supplementation Reduces Fatigue and Muscle Pain in Women With
Early-Stage Breast Cancer - Doctor's Guide, 12/17/07 -
"Treatment of low levels of vitamin D in women with
early stage breast cancer appears to reduce fatigue and muscle pain
associated with aromatase inhibitor therapy" - See
vitamin D products at iHerb.
Pain Makes Some End Breast Cancer Drug - WebMD, 9/6/07 -
"23% of the women in the new study given one of two
aromatase inhibitors -- Aromasin or Femara -- stopped taking their drugs due
to side effects, which also included hot flashes and nausea ... Forty-two
percent of the women reported serious bone and joint problems, such as
severe pain or difficulty opening a jar, and were referred for evaluation by
a rheumatologist"
Hormone Help for Ovarian Cancer? - WebMD, 6/15/07 -
"The patients took a drug called Femara, which is an
aromatase inhibitor, a type of drug that curbs estrogen production ...
monitored the women's blood level of a tumor marker called CA-125, a
substance found in higher concentrations in ovarian cancer than in other
cells ... Eleven of the 42 patients (26%) showed no tumor growth over six
months, based on their CA-125 levels"
Zoledronic Acid Plus Letrozole Concurrent Treatment Prevents Bone Loss -
Doctor's Guide, 12/18/06
New 4-Year Data Confirm Letrozole Cuts Risk of Breast Cancer Recurrence and
Spread of Disease - Doctor's Guide, 10/5/06
Femara Beats Older Breast Cancer Drug - WebMD, 10/3/06
Postmenopausal Women With Breast Cancer Who Switch to Letrozole Tablets
Experience Dramatic Reduction in Risk of Recurrence, Distant Metastasis and
Improvement in Survival - Doctor's Guide, 6/15/06
Bone Loss Associated with Aromatase Inhibitor Therapy for Breast Cancer
Confirmed - Doctor's Guide, 6/4/06 -
"Aromatase inhibitor use was
associated with a relative risk (RR) ratio of 1.3"
Patients Have Longer Disease-Free Survival on Letrozole When They Have
Estrogen Receptor-Positive/Progesterone Receptor-Positive Disease -
Doctor's Guide, 3/27/06
Letrozole Reduces Recurrence More Than Tamoxifen in Early Breast Cancer
- Doctor's Guide, 3/27/06
New Clinical Data Show Benefits of Femara(R) for Women With Breast Cancer
Even After Prolonged Period of No Anti-Cancer Treatment Post-tamoxifen -
Doctor's Guide, 3/23/06
ZO-FAST Trial Shows Early Use of Zoledronic Acid Prevents Bone Loss with
Letrozole - Doctor's Guide, 3/22/06
Letrozole May Be Useful Adjuvant Therapy for Endocrine-Responsive Breast
Cancer - Medscape, 1/3/06
Femara® Receives US Approval as Initial Therapy for Postmenopausal Women
With Early Breast Cancer After Surgery - Doctor's Guide, 12/29/05
Letrozole Better Than Tamoxifen in Reducing Risk of Recurrence for Breast
Cancer Survivors, IBSCG Study Published in New England Journal of Medicine
Shows - Doctor's Guide, 12/29/05
Femara May Be Better Than Tamoxifen - WebMD, 12/28/05
No Changes in Breast Density Seen in Response to Treatment with Letrozole
(Femara) - Doctor's Guide, 12/13/05
Switch from Tamoxifen to Letrozole Results in Significant Improvements in
Hot Flushes, Quality of Life and Mood Among Breast Cancer Patients -
Doctor's Guide, 12/12/05
Letrozole-Bevacizumab Combination Safe and Effective in Women with Hormone
Receptor-Positive Metastatic Breast Cancer - Doctor's Guide, 12/9/05
Femara (Letrozole) Approved for Early Invasive Breast Cancer Post-Surgery
- Doctor's Guide, 12/8/05
Breast Cancer Drug Not for Fertility - WebMD, 11/30/05
Contraindication of Femara (Letrozole) in Premenopausal Women - Doctor's
Guide, 11/28/05
Long-term Consequences of the Aromatase Inhibitors - Medscape, 11/16/05
- "The "short-term toxicities," such
as vasomotor symptoms, venothromboemboli, and gynecologic complications,
favor the use of AIs. However, long-term bone loss, altered lipid profiles,
and possible compromise in sexual functioning appear to be adversely
affected by the AIs"
Aromatase Inhibitors Have Different Cardiovascular Safety Profiles -
Doctor's Guide, 11/2/05
Femara Benefits Younger Women With Breast Cancer - WebMD, 10/17/05
Femara May Reduce Breast Cancer Recurrence - WebMD, 9/7/05
Letrozole More Effective Than Tamoxifen Against Breast Cancer Recurrence
- Medscape, 5/23/05
Primary Letrozole Therapy Compared to Letrozole Plus Oral Cyclophosphamide
in Elderly Women With Breast Cancer - Doctor's Guide, 5/18/05
Significant Reduction in Death and Recurrence Seen in Women Receiving
Letrozole for Breast Cancer - Doctor's Guide, 5/18/05
Femara Beats Tamoxifen for Breast Cancer - WebMD, 5/13/05
Breast Cancer Drug Femara Beats Tamoxifen - WebMD, 1/27/05
Femara (Letrozole) Appears to Provide Disease Free-Survival Advantage in Adjuvant Treatment of Early Breast Cancer - Doctor's Guide, 1/27/05
Letrozole Shows Benefits as Adjuvant Endocrine Therapy for Postmenopausal Receptor-Positive Breast Cancer - Doctor's Guide, 1/27/04
FDA Approves Femara (Letrozole) as Post-Tamoxifen Treatment for Early Breast Cancer - Doctor's Guide, 11/1/04
Emerging Successes of Aromatase Inhibitor Switching Trials Likely to Influence Practice Patterns, Future Trials - Doctor's Guide, 7/29/04
Benefits of Aromatase Inhibitors Should Outweigh Physicians' Concerns About Long-Term Toxicity Issues - Doctor's Guide, 7/29/04
Aromatase Inhibitors Still Superior Over Tamoxifen, but Questions Remain About Estrogen Receptor Factors - Doctor's Guide, 7/27/04
New Aromatase Inhibitors Similarly Effective Despite Differences in Oestrogen Suppression - Doctor's Guide, 6/30/04
FDA Grants Priority Review for Femara (Letrozole) for New Indication as Post-Tamoxifen Treatment for Early Breast Cancer in Postmenopausal Women - Doctor's Guide, 6/29/04
Femara (Letrozole) Appears to Significantly Reduce Spread of Early Breast Cancer After Standard Tamoxifen Treatment in Post-Menopausal Women - Doctor's Guide, 6/23/04
Femara (Letrozole) Addresses Ongoing Risk Of Recurrence, Spread And Mortality From Early Breast Cancer, Beyond 5 Years After Surgery - Doctor's Guide, 6/23/04
Novel Drug Treatment May Increase Girls' Height - Doctor's Guide, 6/21/04
Letrozole Increases Survival Rate in Node-Positive Breast Cancer - Medscape, 6/10/04
Final MA-17 Data Shows Letrozole Reduces Mortality in Women With Node-Positive Breast Cancer - Doctor's Guide, 6/9/04
Breast Cancer Drug May Ease Endometriosis - WebMD, 2/13/04
Adjuvant Letrozole Cuts Risk of Recurrent Breast Cancer - Doctor's Guide, 12/18/03
Femara (Letrozole) Appears to Reduce Breast Cancer Recurrence by Half - Doctor's Guide, 12/15/03
Drug Combo Reduces Recurrence of Breast Cancer - Physician's Weekly, 12/1/03
New Breast Cancer Drug Leaves Questions - HealthDay, 10/17/03
Interim Data Show Improved Disease-Free Survival with Letrozole over Placebo in Post-Tamoxifen Therapy Postmenopausal Breast Cancer Patients - Doctor's Guide, 10/10/03
Breast Cancer Drug Shows Great Promise -
HealthDay, 10/9/03
Femara Prevents Breast Cancer Recurrence - WebMD, 10/9/03
Letrozole Confirmed Superior Over Tamoxifen As First-Line Therapy For Postmenopausal Advanced Breast Cancer - Doctor's Guide, 7/11/03
Health Canada Confirms Treatment With Femera (Letrozole) For Advanced Breast Cancer May Increase Survival - Doctor's Guide, 5/28/03
Letrozole Superior to Tamoxifen Regardless of Hormone Receptor Status - Doctor's Guide, 12/13/02
Letrozole Offers Increased Quality-Adjusted Survival Compared To Tamoxifen - Doctor's Guide, 12/13/02
Adding Letrozole to Docetaxel + Mitoxantrone of Little Benefit in First Line Therapy of Advanced Breast Cancer -
Doctor's Guide, 10/21/02
Letrozole Produces Better Response than Anastrozole in Advanced Breast Cancer - Doctor's Guide, 5/22/02
Head-To-Head Worldwide Study Of The Two Leading Aromatase Inhibitors Shows More Women Respond To Femara (Letrozole) Than Arimidex (Anastrozole) In Advanced Breast Cancer - Doctor's Guide, 5/21/02
Femara (Letrozole) More Effective Than Arimidex (Anastrozole) at Inhibiting Estrogen in Advanced Breast Cancer - Doctor's Guide, 1/31/02
Letrozole Superior Therapy For Postmenopausal Primary Untreated Breast Cancer - Doctor's Guide, 12/17/01
Quality of Life Preserved Among Women Taking Femara (Letrozole) as Second-line Hormonal Therapy for Breast Cancer - Doctor's Guide, 12/14/01
Women With Elevated Serum HER2 Levels Show Reduced Efficacy of Letrozole - Doctor's Guide, 12/12/01
Letrozole (Femara) Should Be First-Line Hormonal Therapy Over Tamoxifen - Doctor's Guide, 12/12/01
Femara® (Letrozole) Cost-Effective, Superior First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women - Doctor's Guide, 10/26/01
Letrozole More Effective Than Tamoxifen - Doctor's Guide, 10/2/01
Anti-Aromatase Agents Cost-Effective For Women With Metastatic Breast Cancer - Doctor's Guide, 5/15/01
Femara (Letrozole Tablets) Demonstrates Superiority Over Tamoxifen in Advanced Breast Cancer - Doctor's Guide, 5/14/01
FDA Approves Femara (Letrozole) For First-Line Treatment For Breast Cancer - Doctor's Guide, 1/11/01
FDA Committee Recommends Femara (Letrozole) For Advanced Breast Cancer - Doctor's Guide, 12/13/00
Femara (Letrozole) Significantly More Effective Than Tamoxifen In Treating Advanced Breast Cancer - Doctor's Guide, 12/7/00
Femara (Letrozole) More Effective Than Tamoxifen As First-Line Treatment For Advanced Breast Cancer - Doctor's Guide, 11/9/00
Femara Effective In Postmenopausal Women With Advanced Breast Cancer - Doctor's Guide, 2/5/98
New Advanced Breast Cancer Drug Now Available - Doctor's Guide, 10/1/97
Abstracts:
Related Sites:
70521
|
